Edgestream Partners’s Novartis NVS Stock Holding History

Edgestream Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-59,479	Closed	-$5.03M	–	569
2022 Q2	$5.03M	Sell	59,479 -15,253	-20%	-$1.34M	0.4%	67
2022 Q1	$6.56M	Buy	+74,732	New	+$6.47M	0.52%	34
2021 Q4	–	Sell	-118,155	Closed	-$9.66M	–	557
2021 Q3	$9.66M	Buy	+118,155	New	+$10.6M	0.6%	39

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Edgestream Partners's NVS Position: Q3 2022 in Review

Edgestream Partners sold out of Novartis (NVS) in Q3 2022, closing a stake of 59,479 shares — an estimated $5.03M sold.

Edgestream Partners first reported a position in NVS in Q3 2021 and held it in 3 quarters. The position peaked at $9.66M in Q3 2021. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.

Edgestream Partners reported no remaining Novartis position as of Q3 2022 after selling out during the quarter.
Edgestream Partners sold 59,479 Novartis shares in Q3 2022, an estimated $5.03M.
Edgestream Partners first reported a position in Novartis in Q3 2021 and held it in 3 quarters.
Edgestream Partners's Novartis position peaked at $9.66M in Q3 2021.
1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.

Based on Edgestream Partners's 13F filing for Q3 2022, filed 14 Nov 2022.